1471-2261-7-28 1471-2261 Research article <p>One-year health status outcomes of unstable angina versus myocardial infarction: a prospective, observational cohort study of ACS survivors</p> Maddox M Thomas thomas.maddox@va.gov Reid J Kimberly kreid@saint-lukes.org Rumsfeld S John john.rumsfeld@va.gov Spertus A John spertusj@umkc.edu

Denver VAMC/University of Colorado Health Science Center, Denver, CO, USA

Mid America Heart Institute of Saint Luke's Hospital, Kansas City, MO, USA

University of Missouri – Kansas City, Kansas City, MO, USA

BMC Cardiovascular Disorders 1471-2261 2007 7 1 28 http://www.biomedcentral.com/1471-2261/7/28 1785066210.1186/1471-2261-7-28
16 1 2007 12 9 2007 12 9 2007 2007 Maddox et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Unstable angina (UA) patients have lower mortality and reinfarction risks than ST-elevation (STEMI) or non-ST elevation myocardial infarction (NSTEMI) patients and, accordingly, receive less aggressive treatment. Little is known, however, about the health status outcomes (angina, physical function, and quality of life) of UA versus MI patients among survivors of an ACS hospitalization.

Methods

In a cohort of 1,192 consecutively enrolled ACS survivors from two Kansas City hospitals, we evaluated the associations between ACS presentation (UA, NSTEMI, and STEMI) and one-year health status (angina, physical functioning and quality of life), one-year cardiac rehospitalization rates, and two-year mortality outcomes, using multivariable regression modeling.

Results

After multivariable adjustment for demographic, hospital, co-morbidity, baseline health status, and treatment characteristics, UA patients had a greater prevalence of angina at 1 year than STEMI patients (adjusted relative risk [RR] = 1.42; 95% CI [1.06, 1.90]) and similar rates as NSTEMI patients (adjusted RR = 1.1; 95% CI [0.85, 1.42]). In addition, UA patients fared no better than MI patients in Short Form-12 physical component scores (UA vs. STEMI score difference -0.05 points; 95% CI [-2.41, 2.3]; UA vs. NSTEMI score difference -1.91 points; 95% CI [-4.01, 0.18]) or Seattle Angina Questionnaire quality of life scores (UA vs. STEMI score difference -1.39 points; 95% CI [-5.63, 2.85]; UA vs. NSTEMI score difference -0.24 points 95% CI [-4.01, 3.54]). Finally, UA patients had similar rehospitalization rates as MI patients (UA vs. STEMI adjusted hazard ratio [HR] = 1.31; 95% CI [0.86, 1.99]; UA vs. NSTEMI adjusted HR = 1.03; 95% CI [0.73, 1.47]), despite better 2-year survival (UA vs. STEMI adjusted HR = 0.51; 95% confidence interval (CI) [0.28, 0.95]; UA vs. NSTEMI adjusted HR = 0.40; 95% CI [0.24, 0.65]).

Conclusion

Although UA patients have better survival rates, they have similar or worse one-year health status outcomes and cardiac rehospitalization rates as compared with MI patients. Clinicians should be aware of the adverse health status outcome risks for UA patients and consider close monitoring for the opportunity to improve their health status and minimize the need for subsequent rehospitalization.

Background

Acute coronary syndrome (ACS) clinical presentations, including ST-elevation myocardial infarction [STEMI], non-ST-elevation myocardial infarction [NSTEMI], and unstable angina [UA], are associated with different mortality and recurrent myocardial infarction (MI) rates 1234. Accordingly, optimal ACS management, as outlined in the American College of Cardiology/American Heart Association guidelines, stratifies and treats patients differently according to their presentation so that those with the greatest mortality risk receive the most aggressive therapy 15678. However, mortality and rehospitalization are not the only clinically important outcomes. Patient health status outcomes, including their symptom burden, functional status, and health-related quality of life, are critical outcomes from the patient's perspective 9101112. Accordingly, patient health status has recently been advocated as a marker of healthcare quality 131415.

Despite its clinical importance, little is known about the association between ACS presentation and health status outcomes, especially among UA patients. Given that many cardiac patients are initially identified during an ACS presentation, characterizing this association from the perspective of this presentation is essential to better prognosticate and treat patients with symptomatic coronary disease. Accordingly, we evaluated one-year health status outcomes in a consecutive cohort of ACS patients as a function of their clinical presentation. Identifying patients at risk for poorer health status could identify the need for improved methods of risk stratification so as to improve care and outcomes in ACS patients.

Methods

Study population and design

The Investigation oF Outcomes from acute coRonary syndroMes (INFORM) registry is a prospective, observational cohort study of consecutively hospitalized ACS patients at two Kansas City hospitals, the Mid America Heart Institute and Truman Medical Center, to identify determinants of health status outcomes among ACS survivors. It was powered for minimal detectable differences of >5 points in SAQ quality of life (disease perception) and angina frequency scores. In total, 10,911 consecutive hospitalized patients who had a troponin blood test performed at either hospital between March 2001 and October 2002 were prospectively screened for a possible ACS. 1199 patients with confirmed ACS (see definitions below) were enrolled in the registry (Figure 1) and underwent detailed interviews and chart abstractions to obtain their socio-demographic, health status, clinical, and treatment characteristics. All data elements conformed to the standards established in the American College of Cardiology Task Force on Clinical Data Standards16. Since our investigation focused on those who survived to hospital discharge, those patients who died during hospitalization (n = 7; 3 STEMI, 3 NSTEMI, and 1 UA) were excluded from the analyses. One year after their index hospitalization, follow-up phone interviews were conducted to collect health status and rehospitalization information. Each participant signed an informed consent to participate in this study and Institutional Review Board approval from both institutions (Saint Luke's Health System Institutional Review Board and the University of Missouri-Kansas City Adult Health Sciences Institutional Review Board) was obtained prior to the conduct of the study.

<p>Figure 1</p>

Flowchart of screened and enrolled patients in the INFORM registry

Flowchart of screened and enrolled patients in the INFORM registry.

Acute coronary syndrome classification

Standard definitions were used to confirm patients' ACS diagnosis 17. STEMI patients presented with suggestive cardiac symptoms, diagnostic electrocardiogram (EKG) changes (ST segment elevation or new-onset left bundle branch block [LBBB]), and a positive troponin blood test (during the course of this investigation, the following assays and thresholds were used by the enrolling centers: cTroponin-I assay >0.15 ng/mL, Advia-Centaur, Bayer Diagnostics, Tarrytown, NY; cTroponin-I assay >0.05 ng/mL, Dade Dimension RXL, Dade Behring Diagnostics, Deerfield, IL; cTroponin-I assay >1.9 ng/mL, Abbott Labs, Abbott Park, IL). NSTEMI patients presented with suggestive cardiac symptoms and/or EKG changes (e.g. ST segment depressions and/or T wave changes), and a positive troponin blood test. UA patients presented with suggestive cardiac symptoms, as defined by at least one of the following: new onset angina (<2 months) of at least Canadian Cardiovascular Society Classification (CCSC) class III, prolonged (>20 minutes) rest angina, recent (<2 months) worsening of angina, or angina that occurred within 2 weeks of a previous MI 18. Although EKG changes were not a requirement for diagnosis, nearly one-half of UA patients had ischemic EKG changes on admission (LBBB 4%, ST-elevations 9%, ST-depressions 12%, T-wave inversions 22%). By definition, all UA patients had a negative troponin blood test. To further increase the specificity of the unstable angina diagnosis, those patients with a diagnostic study that excluded obstructive coronary disease, cardiac perfusion defects, or segmental wall motion abnormalities (e.g. coronary angiography, nuclear or echocardiographic stress testing) (n = 125) or confirmed an alternative explanation for their presentation (e.g. esophagogastroduodenoscopy) were excluded. Three physicians reviewed the charts of all patients for whom diagnostic uncertainty (n = 45) remained and attained consensus on the final diagnosis.

Health status, rehospitalization, and mortality assessment

After excluding expired patients by querying the Social Security Death Master File, surviving patients underwent follow-up telephone interviews to obtain one-year rehospitalization rates and health status outcomes. Health status outcomes were measured using the Seattle Angina Questionnaire (SAQ) and the Short Form-12 Version 2 (SF-12). The SAQ is a 19-item disease-specific health status measure for patients with coronary artery disease (CAD) that has well-established validity, reliability, sensitivity to clinical change, and prognostic value 1319202122. Five domains are assessed: anginal frequency, anginal stability, physical limitation, treatment satisfaction, and disease perception. The scales used in these analyses range from 0–100, where higher scores indicate fewer symptoms and higher quality of life. The SF-12 is a generic health status measure that is converted into physical and mental component scores 23. A score of 50 reflects the United States' population mean, and a deviation of 10 points reflects 1 standard deviation from that mean. Higher scores indicate better physical and mental functioning.

We measured the health status outcomes of symptoms, physical functioning, and health-related quality of life with the SAQ angina frequency scale, the SF-12 physical component scale, and the SAQ disease perception scale, respectively. The SAQ scales of treatment satisfaction and angina stability were less informative to our research question, and thus not analyzed. In addition, the SF-12 physical functioning scale was used instead of the SAQ physical limitation scale because the SF-12 scale was more representative of activities that registry patients performed and the disease-specific SAQ created more missing data for physical function than did the SF-12. One-year cardiac rehospitalization rates were collected by patient self-report at the follow-up interview. Hospitalizations for chest pain, heart failure, myocardial infarction (MI), cardiac revascularization (percutaneous coronary intervention [PCI], or coronary artery bypass graft [CABG]) were defined as cardiac. Hospitalizations for other reasons were coded as non-cardiac. Two-year mortality data was determined by querying the Social Security Administration Death Master File. A final query of the Social Security Death Master File, hospital and outpatient records for vital status and hospitalization data was performed in October 2004.

Statistical analysis

After categorizing patients by their ACS presentation (STEMI, NSTEMI and UA), baseline clinical characteristics were compared. Categorical data were reported as frequencies, and differences were assessed using chi-square tests. Continuous data were reported as means ± standard deviations and differences were assessed using analysis of variance.

To evaluate the independent association between ACS presentation and outcomes, multivariable models were created to adjust for all other differences in socio-demographic (age, race, sex, and insurance status), hospital (Mid-America Heart Institute or Truman Medical Center), clinical (prior MI, prior PCI, prior CABG, congestive heart failure, hypertension, diabetes, hyperlipidemia, cerebrovascular accident/transient ischemic attack, renal failure, anemia, and tobacco use), baseline physical function or quality of life (SF-12 physical functioning scores or SAQ quality of life scores) and treatment (both revascularization (PCI, CABG, or thrombolysis) and discharge medications (angiotensin converting enzyme [ACE] inhibitors, lipid lowering agents, beta-blockers, calcium channel blockers, nitrates, and aspirin)) characteristics. Anemia was defined as hemoglobin values less than the fifth percentile of the sex, race, and age-matched population 24. Categories of variables (socio-demographic, site, clinical, baseline health status, and treatment) were entered sequentially into the model and presented accordingly, in order to illustrate the additive effects of each variable group on the various outcomes.

SAQ angina frequency scores were modeled as a dichotomous outcome of any angina vs. no angina at one year after index ACS hospitalization because of the skewed nature of the measure and our clinical goal of seeking to completely eliminate patients' angina 25. Since one-year angina in our study was a relatively frequent event, we estimated adjusted relative risks directly using a modified Poisson regression model, rather than using logistic regression which estimates adjusted odds ratios 26. SF-12 physical component and SAQ quality of life scores were modeled as continuous variables using multivariable linear regression. Model diagnostics were conducted using residual and normal probability plots.

Unadjusted differences in mortality and rehospitalization rates between ACS classes were described graphically with Kaplan-Meier survival plots and compared using the log-rank test. Adjusted differences in mortality and rehospitalization rates between ACS classes, using the same covariates as the health status models, were compared using multivariable Cox proportional hazards regression models. Cox proportional hazards assumptions were tested using Schoenfeld residuals.

All analyses were performed with SAS version 9.3.1 (SAS Institute, Inc., Cary, NC) and R version 2.1.1 (R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria). Statistical significance for all analyses was assumed when the p value was less than 0.05. Scheffe correction techniques for multiple comparisons were used for pair-wise comparisons.

Missing data

Among the 1192 patients who survived until hospital discharge, 77 (6.5%) died within 12 months of follow-up. Health status outcomes were not imputed for those who died. Thus, our health status results characterize those who survived for at least one year after discharge. Among survivors, 210 patients (17.6%) were not interviewed at one year, because they could not be contacted (73% of non-respondents), or refused to complete the interview (27% of non-respondents). Among those lost-to-follow-up patients, there were no significant differences by ACS presentation.

We explored potential selection biases in the rehospitalization and health status outcomes through the use of sensitivity and propensity model analyses. Sensitivity analysis was performed by imputing poor health status scores to those patients (n = 22) who were too ill to participate in the follow-up interview. Specifically, patients were assigned a SAQ Angina Frequency score indicating presence of angina, an SF-12 physical functioning score of 25, and a SAQ quality of life score of 50; the lowest deciles for each outcome. Regression analyses were repeated using these imputed values and no statistically or clinically significant differences in results were noted (results not shown).

As an alternative approach for handling missing health status data from patients who refused 1-year interviews or could not be contacted, propensity scores were computed using non-parsimonious multivariable logistic regression models to predict the likelihood of unsuccessful follow-up 27. Predictor variables included all available demographic, socio-economic and lifestyle factors, clinical characteristics, vital signs and laboratory studies, disease severity, baseline health status, medication, acute, and non-acute treatments received during patients' initial ACS hospitalization. From these models, a probability of success for completing an interview was calculated. The reciprocal of this probability was then assigned to those patients' scores in the multivariable regression analyses in order to assess for potential observable bias from those lost to follow-up by weighting patients that are similar to those with missing data more heavily 27. These analyses also demonstrated that the missing patients did not impact our primary findings. In light of the consistency of our findings with both imputation and propensity approaches for handling missing data, we have presented only the primary results.

Results

Patient characteristics by ACS presentation

Among the 1192 ACS survivors, 318 (27%) presented with STEMI, 355 (30%) with NSTEMI, and 519 (44%) with UA. Table 1 illustrates the socio-demographic and clinical characteristics, baseline health status scores, revascularization therapies and discharge medications for each ACS class. Demographically, NSTEMI patients were more likely to be older than either STEMI or UA patients, STEMI patients were more likely to be male than either NSTEMI or UA patients, and STEMI patients were more likely to be white compared to UA patients. Clinically, UA patients had significantly higher rates of prior cardiac disease, as indicated by prior myocardial infarction and revascularization, as compared with both STEMI and NSTEMI patients. In addition, UA patients had significantly worse physical functioning and poorer quality of life on admission than either STEMI or NSTEMI patients.

<p>Table 1</p>

Demographic and clinical characteristics by ACS presentation

Variables

STEMI

NSTEMI

UA

ANOVA

n = 321

n = 358

n = 520

p-value


Demographics

Age

60.8 +/- 12.5

63.2 +/- 13.0 *

61.0 +/- 13.0 ‡

p = 0.023

Male

70.7%

56.7% *

59.6% †

p < 0.001

Caucasian

85.3%

81.6%

76.5% †

p = 0.08

Insured

84.4%

89.4%

85.6%

p = 0.132

Employed (full or part-time)

46.3%

36.9% *

34.6% †

p = 0.02

Past medical history

History of myocardial infarction

22.1%

24.3%

44.4% †‡

p < 0.001

History of percutaneous coronary intervention

21.8%

27.7%

46.2% †‡

p < 0.001

History of coronary artery bypass graft

10.0%

18.4% *

25% †‡

p < 0.001

Congestive heart failure

3.7%

7.8% *

8.5% †

p = 0.027

Hypertension

56.4%

63.4%

72.7% †‡

p < 0.001

Diabetes mellitus

19.6%

24.6%

32.7% †‡

p < 0.001

Hyperlipidemia

51.1%

58.1%

68.3% †‡

p < 0.001

Transient ischemic attack

1.2%

1.7%

2.1%

p = 0.65

Cerebrovascular accident

0.9%

2.5%

2.7%

p = 0.208

Chronic obstructive pulmonary disease/asthma

5.6%

12.8% §

12.9% †

p = 0.001

Renal failure

0.9%

2.0%

2.7%

p = 0.214

Anemia

62.2%

61.7%

50.2%

p < 0.001

Tobacco use

68.2%

69.9%

73.2% †‡

p < 0.001

Baseline health status

SAQ angina rates

95.0%

87.4% *

93.1% ‡

p < 0.001

SF-12 physical component scores

42.7 +/- 11.4

39.1 +/- 12.3 *

35.3 +/- 11.9 †‡

p < 0.001

SAQ quality of life scores

50.4 +/- 17.3

53.4 +/- 20.2 *

47.0 +/- 18.8 †‡

p < 0.001

ACS therapies

Primary reperfusion

86.3%

65.1% *

42% †‡

p < 0.001

Percutaneous coronary intervention

63.9%

62% §

40.8% †‡

p < 0.001

Lysis

22.4%

3.1% §

1.2% †‡

p < 0.001

Coronary artery bypass graft

4.4%

3.9%

2.9%

p < 0.001

Discharge meds

Angiotensin converting enzyme inhibitors

18.1%

30.2% *

36.5% †‡

p < 0.001

Lipid lowering

79.8%

77.7%

75.2%

p = 0.191

Beta-blockers

87.5%

84.4%

72.5% †‡

p < 0.001

Calcium channel blockers

10.0%

14.2%

23.7% †‡

p < 0.001

Nitrates

9.3%

12.0%

18.1% †‡

p < 0.001

Acetylsalicylic acid (aspirin)

95.9%

93.9%

92.7%

p = 0.379

*STEMI v NSTEMI p-value < 0.05; †STEMI v UA p-value < 0.05; ‡NSTEMI v UA p-value < 0.05; ANOVA, analysis of variance; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; UA, unstable angina; SAQ, Seattle Angina Questionnaire; SF-12, Short Form 12

Treatments also differed by ACS classification. STEMI patients had the highest revascularization rates and UA patients the lowest (86.3% and 42.0%, respectively). Significant differences in discharge medication prescriptions were also observed. STEMI and NSTEMI patients were more likely to be treated with beta-blockers at discharge, while UA patients received higher rates of ACE-inhibitors, calcium-channel blockers, and nitrates (Table 1).

Mortality and rehospitalization outcomes

UA patients had the lowest two-year mortality rates, but similar one-year rehospitalization rates. At two years, 25 (7.9%) STEMI patients and 45 (12.8%) NSTEMI patients had died as compared with only 35 (6.7%) UA patients (log-rank p-value 0.006; Figure 2a). After multivariable analysis controlling for socio-demographic, site, clinical, and treatment characteristics, UA patients had significantly lower mortality rates compared to STEMI and NSTEMI patients (UA vs. STEMI hazard ratio (HR) = 0.51; 95% confidence interval (CI) [0.28, 0.95]; UA vs. NSTEMI HR = 0.40; 95% CI [0.24, 0.65]) (Figure 2b). At one year, 102 (26.6%) UA patients were rehospitalized for cardiac causes, as compared to 43 (17.6%) STEMI patients and 60 (23.3%) NSTEMI patients (log-rank p-value 0.035: Figure 3a). After multivariable adjustment, UA patients had similar one-year cardiac rehospitalization rates to STEMI and NSTEMI patients (UA vs. STEMI HR = 1.31; 95% CI [0.86, 1.99]; UA vs. NSTEMI HR = 1.03; 95% CI [0.73, 1.47]; Figure 3b).

<p>Figure 2</p>

(a) Unadjusted Kaplan-Meier survival curves of two-year mortality by ACS presentation

(a) Unadjusted Kaplan-Meier survival curves of two-year mortality by ACS presentation (b) Unadjusted and sequential adjustment of two-year mortality by ACS presentation (Model 1 = unadjusted comparison; Model 2 = adjustment for demographic variables (age, race, sex, insurance status); Model 3 = adjustment for demographic and hospital site variables (Mid-America Heart Institute or Truman Medical Center); Model 4 = adjustment for demographic, site, and clinical variables (prior angina, prior myocardial infarction, prior percutaneous coronary intervention, prior coronary artery bypass graft, congestive heart failure, hypertension, diabetes, hyperlipidemia, cerebrovascular accident/transient ischemic attack, renal failure, anemia and tobacco use); Model 6 = adjustment for demographic, site, clinical, and treatment (revascularization [percutaneous coronary intervention, coronary artery bypass graft, thrombolysis] and discharge medications [angiotensin converting enzyme inhibitors, lipid lowering agents, beta-blockers, calcium channel blockers, nitrates, and aspirin]) variables)

<p>Figure 3</p>

(a) Unadjusted Kaplan-Meier survival curves of one-year cardiac rehospitalization by ACS presentation

(a) Unadjusted Kaplan-Meier survival curves of one-year cardiac rehospitalization by ACS presentation (b) Unadjusted and sequential adjustment of one-year cardiac rehospitalization by ACS presentation (Model 1 = unadjusted comparison; Model 2 = adjustment for demographic variables (age, race, sex, insurance status); Model 3 = adjustment for demographic and hospital site variables (Mid-America Heart Institute or Truman Medical Center); Model 4 = adjustment for demographic, site, and clinical variables (prior angina, prior myocardial infarction, prior percutaneous coronary intervention, prior coronary artery bypass graft, congestive heart failure, hypertension, diabetes, hyperlipidemia, cerebrovascular accident/transient ischemic attack, renal failure, anemia and tobacco use); Model 6 = adjustment for demographic, site, clinical, and treatment (revascularization [percutaneous coronary intervention, coronary artery bypass graft, thrombolysis] and discharge medications [angiotensin converting enzyme inhibitors, lipid lowering agents, beta-blockers, calcium channel blockers, nitrates, and aspirin]) variables)

Health status outcomes

One year after discharge, UA patients had worse unadjusted angina rates, physical component scores, and quality of life scores than either STEMI or NSTEMI patients (Figure 4a–c). After sequential multivariable adjustment for all covariates, UA patients were more likely to experience angina than STEMI patients (UA vs. STEMI angina relative risk (RR) = 1.42; 95% CI [1.06, 1.90]). Adjusted angina rates between UA and NSTEMI were similar (UA vs. NSTEMI angina RR = 1.10; 95% CI [0.85, 1.42]) (Figure 4a), as were the remainder of health status scores between all three ACS classes (UA vs. STEMI adjusted mean physical component score difference = -0.05 points, 95% CI [-2.41, 2.30]; UA vs. NSTEMI adjusted mean physical component score difference = -1.91 points, 95% CI [-4.01, 0.18]; UA vs. STEMI adjusted mean quality of life score difference = -1.39 points, 95% CI [-5.63, 2.85]; UA vs. NSTEMI adjusted mean quality of life score difference = -0.24 points, 95% CI [-4.01, 3.54]) (Figure 4b,c).

<p>Figure 4</p>

(a) Unadjusted and sequential adjustment of one-year angina by ACS presentation

(a) Unadjusted and sequential adjustment of one-year angina by ACS presentation (b) Unadjusted and sequential adjustment of one-year physical functioning by ACS presentation (c) Unadjusted and sequential adjustment of one-year quality of life by ACS presentation (Model 1 = unadjusted comparison; Model 2 = adjustment for demographic variables (age, race, sex, insurance status); Model 3 = adjustment for demographic and hospital site variables (Mid-America Heart Institute or Truman Medical Center); Model 4 = adjustment for demographic, site, and clinical variables (prior angina, prior myocardial infarction, prior percutaneous coronary intervention, prior coronary artery bypass graft, congestive heart failure, hypertension, diabetes, hyperlipidemia, cerebrovascular accident/transient ischemic attack, renal failure, anemia and tobacco use); Model 5 = adjustment for demographic, site, clinical, and baseline health status variables (SF-12 physical component score and SAQ quality of life score models only); Model 6 = adjustment for demographic, site, clinical, baseline health status (SF-12 physical component score and SAQ quality of life score models only), and treatment (revascularization [percutaneous coronary intervention, coronary artery bypass graft, thrombolysis] and discharge medications [angiotensin converting enzyme inhibitors, lipid lowering agents, beta-blockers, calcium channel blockers, nitrates, and aspirin]) variables)

Discussion

Although previous studies have documented higher mortality among MI patients as compared to those with UA 123, none have systematically evaluated the association of ACS presentation with health status outcomes. Our study is the first to illustrate that UA patients have a higher prevalence of angina at 1 year than STEMI patients, even after adjustment for numerous differences in patient characteristics and treatment. Furthermore, we found that, in contrast to their better prognosis in terms of survival, UA patients had a similar prevalence of angina as compared with NSTEMI patients and similar one-year physical functioning scores, quality of life scores, and cardiac rehospitalization rates to both STEMI and NSTEMI patients. Our study suggests that since UA patients' favorable prognosis with respect to mortality does not translate to health status outcomes, close follow-up and monitoring of UA patients is needed.

With the recognition of MI patients' elevated mortality risk, the medical community substantially reorganized itself, resulting in community interventions to accelerate the recognition and treatment of potential MIs, emergency department chest pain centers for rapid patient triage, increased access to primary PCI, early institution of anti-platelet treatments and invasive risk stratification, resulting in impressive mortality reductions over the past decades 47282930313233. However, the results of this study highlight the adverse health status outcome risks present in the UA population, as compared with MI patients. Given that these are critical outcomes for patients and providers alike, clinicians should be aware of these risks and should develop interventions to improve the health status outcomes of UA patients.

One previous report has also noted poorer health status outcomes among UA patients. Rumsfeld and colleagues evaluated 2733 ACS patients, using a general health status instrument, the Short Form-36 (SF-36), and followed patients for 7 months after their index hospitalization. They found that a discharge diagnosis of UA, as compared with MI, was associated with a worse SF-36 physical component score 34. Our study strengthens and extends these initial findings by using a cardiac disease-specific instrument, assessing a broader range of health status outcomes (including angina and health-related quality of life in addition to physical functioning), adjusting for a greater number of potential confounders, and conducting observations over a longer follow-up period.

Several characteristics of the UA population may partially explain their worse angina outcomes. The high prevalence of pre-existing CAD and low revascularization rates among UA patients may contribute to their higher angina rates and lower health status scores, though adjustment for these factors did not eradicate the higher angina rates of UA patients compared to STEMI patients 3536. Other unmeasured characteristics of their care, such as less intensive outpatient medical and/or revascularization therapies, decreased medical follow-up, and decreased medication adherence among UA patients, may affect patients' long-term health status and represent important opportunities to improve their outcomes. Further research is needed to evaluate the outpatient care of ACS patients so that greater insights into the potential opportunities to improve the angina rates among UA patients may be uncovered.

Multiple studies have demonstrated improvements in anginal symptoms and subsequent health status among CAD patients with both medical therapy and revascularization, though most studies document greater health status improvements with revascularization strategies as compared to standard medical therapy 373839404142. Mortensen and colleagues noted improved three-year angina rates and SF-36 physical functioning scores among patients with inducible post-infarction ischemia who underwent invasive revascularization 37. Similarly, Kim and colleagues demonstrated improved one-year angina rates and higher one-year quality of life scores among NSTEMI/UA patients randomized to an invasive revascularization treatment strategy 42. Given the success of these strategies in improving health status outcomes among MI and stable CAD patients, randomized studies of these and other strategies on health status outcomes among UA patients should be considered. Concurrently, integration of objective health status assessment into the care of ACS patients could offer a tool to identify patients with residual symptoms and to potentially indicate a need for additional therapy to improve UA patients' rehospitalization rates and quality of life.

Our study has several potential limitations. First, it was conducted at only 2 Midwestern centers, which may limit the generalizability of our findings to other centers. Second, despite follow-up rates greater than 80%, missing data can potentially introduce bias. Although our sensitivity and propensity analyses suggested no important differences, we cannot rule out the possibility of unmeasured confounding from those patients without follow-up. Third, cardiac rehospitalization data was assessed by patient self-report, and thus subject to potential misclassification and recall bias. However, trained data collectors conducted phone interviews, thus minimizing this risk. Finally, we did not have detailed data about the outpatient treatment regimens of our patients, including the frequency of follow-up medical visits or their medication use over the year after discharge. Further research will need to define whether the intensity or quality of post-discharge care differs across the spectrum of ACS patients.

Conclusion

In conclusion, we found that UA patients had a higher prevalence of angina than STEMI patients and similar physical functioning, quality of life, and cardiac rehospitalization outcomes as compared with both STEMI and NSTEMI patients one year after ACS presentation. Since multiple treatments, including medications and revascularization, are available to improve patients' angina, these findings identify an important potential opportunity for improving the quality of care for UA patients. Future studies to evaluate the impact of these interventions specifically in UA patients are needed. Until then, clinicians should remain as vigilant for persistent angina, functional limitations and poor quality of life among UA patients as they are among MI patients.

Abbreviations

ACS, acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; UA, unstable angina

Competing interests

Dr. Spertus discloses he has leadership responsibilities for CV Outcomes, Inc., Health Outcomes Sciences and Outcomes Instruments; is a consultant for Amgen, United Healthcare, and Otsuka; receives research grant support from the National Institutes of Health, Amgen, Lilly, Roche Diagnostics, and the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR); and owns the copyrights for the Seattle Angina Questionnaire, the Kansas City Cardiomyopathy Questionnaire, and the Peripheral Artery Questionnaire. The other authors declare that they have no competing interests.

Authors' contributions

TMM and JAS conceived of the study, participated in its design and coordination, and drafted the manuscript. KJR performed the statistical analysis and assisted with manuscript drafts. JSR assisted with manuscript drafts and provided critical input. All authors read and approved the final manuscript.

Acknowledgements

Financial Support: This project was principally supported by R-01 HS11282-01 from the Agency for Healthcare Research and Quality.

<p>Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators</p> Armstrong PW Fu Y Chang WC Topol EJ Granger CB Betriu A Van de Werf F Lee KL Califf RM Circulation 1998 98 1860 8 9799205 <p>Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective</p> Furman MI Dauerman HL Goldberg RJ Yarzebski J Lessard D Gore JM J Am Coll Cardiol 2001 37 1571 80 10.1016/S0735-1097(01)01203-7 11345367 <p>Prognosis after first myocardial infarction. Comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study</p> Berger CJ Murabito JM Evans JC Anderson KM Levy D Jama 1992 268 1545 51 10.1001/jama.268.12.1545 1518109 <p>Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3</p> Rogers WJ Canto JG Lambrew CT Tiefenbrunn AJ Kinkaid B Shoultz DA Frederick PD Every N J Am Coll Cardiol 2000 36 2056 63 10.1016/S0735-1097(00)00996-7 11127441 <p>A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry</p> Eagle KA Lim MJ Dabbous OH Pieper KS Goldberg RJ Van de Werf F Goodman SG Granger CB Steg PG Gore JM Budaj A Avezum A Flather MD Fox KA Jama 2004 291 2727 33 10.1001/jama.291.22.2727 15187054 <p>The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making</p> Antman EM Cohen M Bernink PJ McCabe CH Horacek T Papuchis G Mautner B Corbalan R Radley D Braunwald E Jama 2000 284 835 42 10.1001/jama.284.7.835 10938172 <p>ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)</p> Antman EM Anbe DT Armstrong PW Bates ER Green LA Hand M Hochman JS Krumholz HM Kushner FG Lamas GA Mullany CJ Ornato JP Pearle DL Sloan MA Smith SC Jr. Alpert JS Anderson JL Faxon DP Fuster V Gibbons RJ Gregoratos G Halperin JL Hiratzka LF Hunt SA Jacobs AK Circulation 2004 110 82 292 10.1161/01.CIR.0000134791.68010.FA <p>Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial</p> Morrow DA Cannon CP Rifai N Frey MJ Vicari R Lakkis N Robertson DH Hille DA DeLucca PT DiBattiste PM Demopoulos LA Weintraub WS Braunwald E Jama 2001 286 2405 12 10.1001/jama.286.19.2405 11712935 <p>Selecting end points in clinical trials: What evidence do we really need to evaluate a new treatment?</p> Spertus J Am Heart J 2001 142 745 7 10.1067/mhj.2001.119135 11685157 <p>Health values of hospitalized patients 80 years or older. HELP Investigators. Hospitalized Elderly Longitudinal Project</p> Tsevat J Dawson NV Wu AW Lynn J Soukup JR Cook EF Vidaillet H Phillips RS Jama 1998 279 371 5 10.1001/jama.279.5.371 9459470 <p>Health status and clinical practice: when will they meet?</p> Rumsfeld JS Circulation 2002 106 5 7 10.1161/01.CIR.0000020805.31531.48 12093759 <p>Impact of angina burden and other factors on treatment satisfaction after acute coronary syndromes</p> Beinart SC Sales AE Spertus JA Plomondon ME Every NR Rumsfeld JS Am Heart J 2003 146 646 52 10.1016/S0002-8703(03)00256-4 14564318 <p>Health status predicts long-term outcome in outpatients with coronary disease</p> Spertus JA Jones P McDonell M Fan V Fihn SD Circulation 2002 106 43 9 10.1161/01.CIR.0000020688.24874.90 12093768 <p>Challenges and opportunities in quantifying the quality of care for acute myocardial infarction: summary from the Acute Myocardial Infarction Working Group of the American Heart Association/American College of Cardiology First Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke</p> Spertus JA Radford MJ Every NR Ellerbeck EF Peterson ED Krumholz HM J Am Coll Cardiol 2003 41 1653 63 10.1016/S0735-1097(03)00415-7 12742310 <p>Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease</p> Califf RM Mark DB Harrell FE Jr. Hlatky MA Lee KL Rosati RA Pryor DB J Am Coll Cardiol 1988 11 20 6 3335698 <p>American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee)</p> Cannon CP Battler A Brindis RG Cox JL Ellis SG Every NR Flaherty JT Harrington RA Krumholz HM Simoons ML Van De Werf FJ Weintraub WS Mitchell KR Morrisson SL Brindis RG Anderson HV Cannom DS Chitwood WR Cigarroa JE Collins-Nakai RL Ellis SG Gibbons RJ Grover FL Heidenreich PA Khandheria BK Knoebel SB Krumholz HL Malenka DJ Mark DB Mckay CR Passamani ER Radford MJ Riner RN Schwartz JB Shaw RE Shemin RJ Van Fossen DB Verrier ED Watkins MW Phoubandith DR Furnelli T J Am Coll Cardiol 2001 38 2114 2130 10.1016/S0735-1097(01)01702-8 11738323 <p>Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction</p> Alpert JS Thygesen K Antman E Bassand JP J Am Coll Cardiol 2000 36 959 69 10.1016/S0735-1097(00)00804-4 10987628 <p>Unstable angina. A classification</p> Braunwald E Circulation 1989 80 410 4 2752565 <p>Monitoring the quality of life in patients with coronary artery disease</p> Spertus JA Winder JA Dewhurst TA Deyo RA Fihn SD Am J Cardiol 1994 74 1240 1244 10.1016/0002-9149(94)90555-X 7977097 <p>The Seattle angina questionnaire: reliability and validity in women with chronic stable angina</p> Kimble LP Dunbar SB Weintraub WS McGuire DB Fazio S De AK Strickland O Heart Dis 2002 4 206 11 10.1097/00132580-200207000-00002 12147179 <p>Comparison of three quality of life instruments in stable angina pectoris: Seattle Angina Questionnaire, Short Form Health Survey (SF-36), and Quality of Life Index-Cardiac Version III</p> Dougherty CM Dewhurst T Nichol WP Spertus J J Clin Epidemiol 1998 51 569 75 10.1016/S0895-4356(98)00028-6 9674663 <p>Development and evaluation of the Seattle Angina Questionnaire: A new functional status measure for coronary artery disease</p> Spertus JA Winder JA Dewhurst TA Deyo RA Prodzinski J McDonell M Fihn SD J Am Coll Cardiol 1995 25 333 341 10.1016/0735-1097(94)00397-9 7829785 Ware JE How to Score Version 2 of the SF-12 Health Survey Lincoln, RI, QualityMetric Incorporated 2002 <p>The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?</p> Beutler E Waalen J Blood 2006 107 1747 50 1895695 16189263 10.1182/blood-2005-07-3046 <p>Prevalence and predictors of angina pectoris one month after myocardial infarction</p> Spertus JA Dawson J Masoudi FA Krumholz HM Reid KJ Peterson ED Rumsfeld JS Am J Cardiol 2006 98 282 288 10.1016/j.amjcard.2006.01.099 16860010 <p>A Modified Poisson Regression Approach to Prospective Studies with Binary Data</p> Zou G Am J Epidemiology 2004 159 702 706 10.1093/aje/kwh090 <p>Model-based direct adjustment</p> Rosenbaum PR J Am Stat Assoc 1987 82 387 394 10.2307/2289440 <p>Impact on the care of the emergency department chest pain patient from the chest pain evaluation registry (CHEPER) study</p> Graff LG Dallara J Ross MA Joseph AJ Itzcovitz J Andelman RP Emerman C Turbiner S Espinosa JA Severance H Am J Cardiol 1997 80 563 8 10.1016/S0002-9149(97)00422-0 9294982 <p>A clinical trial of a chest-pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators</p> Farkouh ME Smars PA Reeder GS Zinsmeister AR Evans RW Meloy TD Kopecky SL Allen M Allison TG Gibbons RJ Gabriel SE N Engl J Med 1998 339 1882 8 10.1056/NEJM199812243392603 9862943 <p>Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction</p> Waters RE Singh KP Roe MT Lotfi M Sketch MH Jr. Mahaffey KW Newby LK Alexander JH Harrington RA Califf RM Granger CB J Am Coll Cardiol 2004 43 2153 9 10.1016/j.jacc.2003.12.057 15193673 <p>Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators</p> Lancet 1999 354 708 15 10.1016/S0140-6736(99)07349-3 10475181 <p>Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban</p> Cannon CP Weintraub WS Demopoulos LA Vicari R Frey MJ Lakkis N Neumann FJ Robertson DH DeLucca PT DiBattiste PM Gibson CM Braunwald E N Engl J Med 2001 344 1879 87 10.1056/NEJM200106213442501 11419424 <p>ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina)</p> Braunwald E Antman EM Beasley JW Califf RM Cheitlin MD Hochman JS Jones RH Kereiakes D Kupersmith J Levin TN Pepine CJ Schaeffer JW Smith EE Steward DE Theroux P Gibbons RJ Alpert JS Faxon DP Fuster V Gregoratos G Hiratzka LF Jacobs AK Smith SC Jr. J Am Coll Cardiol 2002 40 1366 74 10.1016/S0735-1097(02)02336-7 12383588 <p>Predictors of quality of life following acute coronary syndromes</p> Rumsfeld JS Magid DJ Plomondon ME O'Brien MM Spertus JA Every NR Sales AE Am J Cardiol 2001 88 781 4 10.1016/S0002-9149(01)01852-5 11589849 <p>ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty)</p> Smith SC Jr. Dove JT Jacobs AK Kennedy JW Kereiakes D Kern MJ Kuntz RE Popma JJ Schaff HV Williams DO Gibbons RJ Alpert JP Eagle KA Faxon DP Fuster V Gardner TJ Gregoratos G Russell RO J Am Coll Cardiol 2001 37 2215 39 10.1016/S0735-1097(01)01344-4 11419905 <p>Long-term propranolol therapy for angina pectoris</p> Warren SG Brewer DL Orgain ES Am J Cardiol 1976 37 420 6 10.1016/0002-9149(76)90293-9 816188 <p>Health related quality of life after conservative or invasive treatment of inducible postinfarction ischaemia. DANAMI study group</p> Mortensen OS Madsen JK Haghfelt T Grande P Saunamaki K Haunso S Hjelms E Arendrup H Heart 2000 84 535 40 1729482 11040017 10.1136/heart.84.5.535 <p>Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina</p> Pocock SJ Henderson RA Clayton T Lyman GH Chamberlain DA J Am Coll Cardiol 2000 35 907 14 10.1016/S0735-1097(99)00637-3 10732887 <p>Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial</p> Lancet 2001 358 951 7 10.1016/S0140-6736(01)06100-1 11583747 <p>Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial</p> Rinfret S Grines CL Cosgrove RS Ho KK Cox DA Brodie BR Morice MC Stone GW Cohen DJ J Am Coll Cardiol 2001 38 1614 21 10.1016/S0735-1097(01)01599-6 11704371 <p>Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial</p> Zhang Z Mahoney EM Stables RH Booth J Nugara F Spertus JA Weintraub WS Circulation 2003 108 1694 700 10.1161/01.CIR.0000087600.83707.FD 12975252 <p>Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3)</p> Kim J Henderson RA Pocock SJ Clayton T Sculpher MJ Fox KA J Am Coll Cardiol 2005 45 221 8 10.1016/j.jacc.2004.10.034 15653019

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2261/7/28/prepub